| [1] |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
|
| [2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [3] |
Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future[J]. Ann Surg, 2011, 253(3): 453-469.
|
| [4] |
丛文铭，吴孟超．肝癌术后复发的发生机制及临床病理学意义[J]．中国实用外科杂志，2012, 32(10): 809-811.
|
| [5] |
Chen X, Chen Y, Li Q, et al. Radiofrequency ablation versus surgical resection for intrahepatic hepatocellular carcinoma recurrence:a meta-analysis[J]. J Surg Res, 2015, 195(1): 166-174.
|
| [6] |
Zou Q, Li J, Wu D, et al. Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Ann Surg Oncol, 2016, 23(8): 2618-2626.
|
| [7] |
Hanyong S, Wanyee L, Siyuan F, et al. A prospective randomized controlled trial: comparison of two different methods of hepatectomy[J]. Eur J Surg Oncol, 2015, 41(2): 243-248.
|
| [8] |
Zhang J, Zhou ZG, Huang ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma[J]. Chin J Cancer, 2016(35): 25.
|
| [9] |
Bhangui P, Allard MA, Vibert E, et al. Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes?[J]. Ann Surg, 2016, 264(1): 155-163.
|
| [10] |
Chan DL, Alzahrani NA, Morris DL, et al. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2014, 29(1): 31-41.
|
| [11] |
Fukuhara T, Aikata H, Hyogo H, et al. Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: comparison with primary cases[J]. Eur J Radiol, 2015, 84(8): 1540-1545.
|
| [12] |
Thomasset SC, Dennison AR, Garcea G. Ablation for recurrent hepatocellular carcinoma: a systematic review of clinical efficacy and prognostic factors[J]. World J Surg, 2015, 39(5): 1150-1160.
|
| [13] |
Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial[J]. Gut, 2017, 66(6): 1172-1173.
|
| [14] |
Choi JW, Park JY, Ahn SH, et al. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection[J]. Am J Clin Oncol, 2009, 32(6):564-569.
|
| [15] |
Tian X, Dai Y, Wang DQ, et al. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment:a meta-analysis[J]. Drug Des Devel Ther, 2015(9): 4431-4440.
|
| [16] |
Koh PS, Chan AC, Cheung TT, et al. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis[J]. HPB, 2016, 18(1): 72-78.
|
| [17] |
Wang K, Liu G, Li J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study[J]. Eur J Surg Oncol, 2015, 41(2): 236-242.
|
| [18] |
Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 151(6): 1155-1163, e2.
|
| [19] |
Su TS, Liang P, Lu HZ, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients[J]. J Surg Oncol, 2016, 113(2): 181-187.
|
| [20] |
Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J]. J Clin Oncol, 2013, 31(13): 1631-1639.
|
| [21] |
Huan HB, Lau WY, Xia F, et al. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(39): 14505-14509.
|
| [22] |
Palmer DH. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(23): 2498.
|
| [23] |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
|
| [24] |
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66.
|
| [25] |
Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma[J].J Clin Oncol, 2015, 33(6): 559-566.
|
| [26] |
Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results ofa randomized phase III trial[J]. J Clin Oncol, 2015, 33(2): 172-179.
|
| [27] |
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508.
|
| [28] |
Katz SC, Burga RA, McCormack E, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases[J]. Clin Cancer Res, 2015, 21(14): 3149-3159.
|